☆ 4.7 Article

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Respiratory System

Effects of elexacaf tor/tezacaf tor/ivacaf tor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI

Carmen Streibel et al.

Summary: This study aimed to evaluate the treatment effect of elexacaftor/tezacaftor/ivacaftor combination regimen on children with cystic fibrosis. The results showed significant improvements in lung function and structural and functional MRI parameters following ELX/TEZ/IVA treatment. The study suggests that functional and structural MRI, in addition to lung function tests, is a suitable tool for monitoring treatment response.

JOURNAL OF CYSTIC FIBROSIS (2023)

Add to Collection

Editorial Material Pediatrics

Reply to migration is not the perfect answer: Optimized methodology to assess LCI agreement between corrected legacy multiple breath nitrogen washout data and that directly collected on updated software

Ediane De Queiroz Andrade et al.

PEDIATRIC PULMONOLOGY (2023)

Add to Collection

Article Respiratory System

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting

Paul McNally et al.

Summary: In this real-world study, the use of LUM/IVA in children aged 6-11 with CF resulted in improvements in air trapping on CT but worsening in bronchiectasis scores, suggesting that LUM/IVA treatment can improve respiratory function but cannot prevent the progression of bronchiectasis.

RESPIRATORY RESEARCH (2023)

Add to Collection

Article Critical Care Medicine

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis

David P. Nichols et al.

Summary: The study demonstrates significant improvements in lung function, respiratory symptoms, and body mass index in CF patients using ETI therapy, regardless of their familiarity with modulators or prior drug use. Significant reductions in sweat chloride concentration were also observed, correlating with improved lung function in the overall study population.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Add to Collection

Article Respiratory System

Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis

Alienor Campredon et al.

Summary: The study evaluated lung structural changes after 1 year of lumacaftor-ivacaftor treatment and identified morphological phenotypes associated with treatment response using unsupervised machine learning. The results showed significant improvement in bronchial disease on chest CT after 1-year treatment with lumacaftor-ivacaftor, and radiomics features on pre-therapeutic CT scans may help predict lung function response to the medication.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Critical Care Medicine

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles

Simon Y. Graeber et al.

Summary: ELX/TEZ/IVA improves CFTR function in patients with cystic fibrosis, leading to improved lung ventilation and morphology.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Add to Collection

Article Respiratory System

Artificial intelligence in computed tomography for quantifying lung changes in the era of CFTR modulators

Gael Dournes et al.

Summary: This study aimed to validate a fully automated artificial intelligence (AI)-driven scoring system of CF lung disease severity. The results showed that the AI-driven volumetric quantification had good correlations with visual imaging scoring and pulmonary function tests, providing a robust outcome for CF-related disease in the era of effective CF transmembrane conductance regulator modulator therapy.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report

Romain Bec et al.

Summary: This study evaluated the changes in lung CT scans of patients with cystic fibrosis (CF) after receiving elexacaftor-tezacaftor-ivacaftor (ETI) therapy for one year. The results showed that ETI treatment reduced mucus plugging and peribronchial thickening, improved pulmonary and sinus morphological abnormalities, and significantly improved clinical and functional parameters.

EUROPEAN JOURNAL OF RADIOLOGY (2022)

Add to Collection

Letter Critical Care Medicine

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial

Matthias Griese et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

Pierre-Regis Burgel et al.

Summary: An observational study in France found that the use of elexacaftor-tezacaftor-ivacaftor in CF patients led to significant improvements in lung function and weight within a short period of time, with most patients no longer requiring long-term oxygen, noninvasive ventilation, and/or enteral tube feeding. Compared to the previous two years, there was a twofold decrease in the number of lung transplantations in CF patients in 2020.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/lvacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

Edith T. Zemanick et al.

Summary: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and efficacious in children aged 6 through 11 with at least one F508del-CFTR allele, supporting its use in this patient population. The treatment improved lung function, respiratory scores, lung clearance, sweat chloride levels, and body mass index in these children over the 24-week period. The safety and pharmacokinetic profiles were consistent with those observed in older patients.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor

Francois Arnaud et al.

Summary: The study conducted a retrospective observational study in two French reference centers in CF in Marseille hospitals, showing that treatment with lumacaftor-ivacaftor was associated with a significant improvement in the total CT score, mainly related to an improvement in mucous pluggings. Peribronchial wall thickening also significantly improved in the adult group.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study

Harm A. W. M. Tiddens et al.

PLOS ONE (2020)

Add to Collection

Article Respiratory System

Guidance for computed tomography (CT) imaging of the lungs for patients with cystic fibrosis (CF) in research studies

Marcel van Straten et al.

Journal of Cystic Fibrosis (2019)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry G. M. Heijerman et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

P. G. Middleton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Critical Care Medicine

CORK Study in Cystic Fibrosis Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor

Nicola J. Ronan et al.

CHEST (2018)

Add to Collection

Article Pediatrics

Spirometer Guided Chest Imaging in Children: It Is Worth the Effort!

Elizabeth Salamon et al.

PEDIATRIC PULMONOLOGY (2017)

Add to Collection

Article Respiratory System

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor

Meredith C. Fidler et al.

JOURNAL OF CYSTIC FIBROSIS (2017)

Add to Collection

Article Medicine, General & Internal

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Jennifer L. Taylor-Cousar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Respiratory System

Association between spirometry controlled chest CT scores using computer-animated biofeedback and clinical markers of lung disease in children with cystic fibrosis

Thomas Kongstad et al.

EUROPEAN CLINICAL RESPIRATORY JOURNAL (2017)

Add to Collection

Letter Respiratory System

Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor

Guillaume Chassagnon et al.

EUROPEAN RESPIRATORY JOURNAL (2016)

Add to Collection

Article Multidisciplinary Sciences

A Systematic Approach to Multiple Breath Nitrogen Washout Test Quality

Renee Jensen et al.

PLOS ONE (2016)

Add to Collection

Article Critical Care Medicine

PRAGMA-CF A Quantitative Structural Lung Disease Computed Tomography Outcome in Young Children with Cystic Fibrosis

Tim Rosenow et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)

Add to Collection

Article Respiratory System

Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation

Shahid I. Sheikh et al.

JOURNAL OF CYSTIC FIBROSIS (2015)

Add to Collection

Article Respiratory System

Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype

Edward F. McKone et al.

JOURNAL OF CYSTIC FIBROSIS (2015)

Add to Collection

Article Medicine, General & Internal

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

C. E. Wainwright et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Editorial Material Critical Care Medicine

Ivacaftor Imaging Response in Cystic Fibrosis

Siobhan Hoare et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)

Add to Collection

Article Respiratory System

Consensus statement for inert gas washout measurement using multiple- and single-breath tests

Paul D. Robinson et al.

EUROPEAN RESPIRATORY JOURNAL (2013)

Add to Collection

Article Medicine, General & Internal

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

Frank J. Accurso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Respiratory System

Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis

P. M. Gustafsson et al.

THORAX (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.